WealthCollab’s Acadia Pharmaceuticals ACAD Stock Holding History

WealthCollab’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5	Closed	-$112	–	971
2026 Q1	$112	Buy	+5	New	+$119	﹤0.01%	967
2025 Q2	–	Sell	-384	Closed	-$6.38K	–	949
2025 Q1	$6.38K	Hold	384	–	–	﹤0.01%	563
2024 Q4	$7.05K	Hold	384	–	–	﹤0.01%	521
2024 Q3	$5.91K	Buy	+384	New	+$6.41K	﹤0.01%	574
2024 Q2	–	Sell	-93	Closed	-$1.72K	–	861
2024 Q1	$1.72K	Hold	93	–	–	﹤0.01%	770
2023 Q4	$2.91K	Buy	+93	New	+$2.22K	﹤0.01%	681

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

WealthCollab's ACAD Position: Q2 2026 in Review

WealthCollab sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 5 shares — an estimated $112 sold.

WealthCollab first reported a position in ACAD in Q4 2023 and held it in 6 quarters. The position peaked at $7.05K in Q4 2024. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

WealthCollab reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
WealthCollab sold 5 Acadia Pharmaceuticals shares in Q2 2026, an estimated $112.
WealthCollab first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 6 quarters.
WealthCollab's Acadia Pharmaceuticals position peaked at $7.05K in Q4 2024.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on WealthCollab's 13F filing for Q2 2026, filed 10 Aug 2026.